加载中
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
前收盘价
US$27.28
+US$0.89 · +3.37%
盘中时间采用ET。市场数据可能有所延迟。
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
日内区间
当前US$27.28
52周区间
当前US$27.28
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.56亿 USD | 2.08亿 USD | 2.17亿 USD | 1.81亿 USD | 1.38亿 USD |
| 销货成本 | 1.13亿 USD | 7545.6万 USD | 7597.4万 USD | 7993.3万 USD | 7231.1万 USD |
| 毛利 | 1.43亿 USD | 1.32亿 USD | 1.41亿 USD | 1.01亿 USD | 6562万 USD |
| 研究与开发 | 1.73亿 USD | 2.02亿 USD | 1.82亿 USD | 1.26亿 USD | 9090.4万 USD |
| 销售、一般及管理费用 | 1.36亿 USD | 1.4亿 USD | 1.36亿 USD | 1.21亿 USD | 8615.9万 USD |
| 营业费用 | 3.1亿 USD | 3.41亿 USD | 3.18亿 USD | 2.48亿 USD | 1.77亿 USD |
| 利息收入 | — | — | — | 395万 USD | 105.7万 USD |
| 利息支出 | — | — | — | 3000 USD | — |
| 折旧和摊销 | 602.2万 USD | 615.9万 USD | 555.2万 USD | 434.4万 USD | 284.7万 USD |
| 营业利润 | −1.67亿 USD | −2.09亿 USD | −1.77亿 USD | −1.47亿 USD | −1.11亿 USD |
| 净利润 | −1.03亿 USD | −1.87亿 USD | 4072万 USD | −1.49亿 USD | −1亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$19.00
下跌空间 30.35%报告持有此股票敞口的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR8997.87万0.09%1031.91亿 USD0.06%US$137.55+0.17%
ARK Genomic Revolution ETFARKG5925.86万2.89%15.57亿 USD0.75%US$51.30+4.08%
iShares Russell 2000 ETFIWM4041.25万0.05%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI3831.88万0.00%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB2785.67万0.01%1853亿 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK1600.65万0.04%447亿 USD0.05%US$344.74+1.22%
iShares Russell 2000 Growth ETFIWO1410.03万0.10%139.17亿 USD0.24%US$356.78+0.94%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM1389.78万0.09%158.4亿 USD0.03%US$53.45+0.17%iShares Core S&P Small-Cap ETFIJRARK Genomic Revolution ETFARKGiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKiShares Russell 2000 Growth ETFIWOState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
